With the business potentially at an important milestone, we thought we'd take a closer look at Vertex, Inc.'s (NASDAQ:VERX) future prospects. Vertex, Inc., together with its subsidiaries, provides ...

Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three ...

NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

Vertex Pharmaceuticals Incorporated is downgraded from Buy to Hold due to mounting headwinds and pipeline uncertainties. Vertex faces pressure from potential U.S. drug pricing reforms and tariffs, ...

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of ...

Vertex Pharmaceuticals recently announced that the FDA has granted Breakthrough Therapy Designation to povetacicept for IgA nephropathy, along with key clinical advancements in its kidney disease ...

The Punjab Central Business District Development Authority (PCBDDA), commonly known as Central Business District Punjab (CBD Punjab), has taken another bold step in reshaping skyline of the Punjab's ...

- Food and Drug Administration granted Breakthrough Therapy Designation for povetacicept in IgA nephropathy; on track to file for accelerated approval in the U.S. in H1 2026 if 36-week interim ...

IF YOU LIVE NORTH OF THE RIVER. DONNA. JAMIE. THANK YOU. WE DO HAVE BREAKING NEWS OUT OF OVERLAND PARK. A WOMAN IS IN THE HOSPITAL FOR SMOKE INHALATION AFTER AN APARTMENT FIRE. JUST AFTER ONE THIS ...

Kapiva, a healthcare brand focused on Ayurveda-based products, has raised $60 million in a Series D funding round. The round included $28 million in primary capital and was led by 360 ONE Asset and ...

Fintel reports that on September 25, 2025, Leerink Partners upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Market Perform to Outperform. Analyst Price Forecast Suggests 30.19% ...